Vestor Capital LLC reduced its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 81.6% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 73,162 shares of the healthcare product maker’s stock after selling 323,830 shares during the period. Vestor Capital LLC’s holdings in Abbott Laboratories were worth $7,511,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of ABT. Brighton Jones LLC increased its position in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares in the last quarter. United Bank grew its holdings in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after acquiring an additional 2,001 shares during the period. Main Street Financial Solutions LLC raised its holdings in shares of Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its holdings in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after buying an additional 292,547 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
More Abbott Laboratories News
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Abbott remains a favored income stock among analysts, with TipRanks highlighting its Dividend Aristocrat status and recurring cash distributions. 3 Strong Buy Dividend Aristocrat Stocks to Power Your Cash Flow
- Positive Sentiment: Erste Group Bank raised its fiscal 2026 EPS estimate to $5.52 from $5.47 and nudged its fiscal 2027 estimate to $6.06 from $6.05, broadly confirming consensus expectations.
- Positive Sentiment: UBS issued a Buy rating, while TD Cowen maintained its Buy rating and a $115 price target, citing a strengthening nutrition franchise and additional 2026 growth drivers. UBS Issues a Buy Rating on Abbott Laboratories Abbott Laboratories Buy Rating Backed by Growth Drivers
- Positive Sentiment: Abbott recently exceeded quarterly EPS and revenue expectations, with revenue growth of 13% year over year, supporting the case for continued earnings momentum.
- Neutral Sentiment: Abbott has begun a roughly 1,000-patient real-world TriClip study to evaluate safety and performance in heart-valve repair. The study could strengthen the product’s positioning, but it also underscores intensifying competition from Edwards. Abbott Starts TriClip Study Amid Rising Competition
- Negative Sentiment: UBS has lowered its expectations for Abbott’s stock price, creating a counterweight to the Buy rating and other positive analyst revisions. The conflicting views may be contributing to investor caution.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on ABT
Abbott Laboratories Stock Down 2.0%
Shares of NYSE ABT opened at $105.83 on Friday. The stock’s fifty day moving average is $93.08 and its 200 day moving average is $100.58. The stock has a market capitalization of $183.12 billion, a P/E ratio of 34.25, a PEG ratio of 2.09 and a beta of 0.61. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.01 and a current ratio of 1.38. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
